PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “LYSERGIC ACID DIETHYLAMIDE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources

Binding of [(3)H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults.

Possible age effects on binding of [(3)H]lysergic acid diethylamide ([(3)H]LSD) to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites were studied in platelets from healthy children (11-12 years of age), adolescents (16-17 years of age) and adults. Significant overall age effects were found both for the number of binding sites (B(max)) for [(3)H]LSD binding (p < 0.001), the affinity constant (K(d)) for [(3)H]LSD binding (p < 0.001), B(max) for [(3)H]paroxetine binding (p < 0.001) and K(d) for [(3)H] paroxetine binding (p = 0.006). In general, there was a decrease in B(max) with increasing age, which predominantly occurred between the ages 11-12 years and 16-17 years for the 5-HT(2A) receptor, and after 16-17 years of age for the serotonin uptake site. These developmental changes might have an impact on the effect of treatment with serotonergic drugs in children and adolescents. When the platelet serotonin variables investigated are employed in studies in children or adolescents, age matching or, alternatively, introduction of age control in the statistical analysis should be performed.

Adolescent↗

Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.

The ability of hallucinogens to increase extracellular glutamate in the prefrontal cortex (PFC) was assessed by in vivo microdialysis. The hallucinogen lysergic acid diethylamide (LSD; 0.1 mg/kg, i.p.) caused a time-dependent increase in PFC glutamate that was blocked by the 5-HT(2A) antagonist M100907 (0.05 mg/kg, i.p.). Similarly, the 5-HT(2A/C) agonist [-]-2,5-dimethoxy-4-methylamphetamine (DOM; 0.6 mg/kg, i.p.), which is a phenethylamine hallucinogen, increased glutamate to 206% above saline-treated controls. When LSD (10 microM) was directly applied to the PFC by reverse dialysis, a rapid increase in PFC glutamate levels was observed. Glutamate levels in the PFC remained elevated after the drug infusion was discontinued. These data provide direct evidence in vivo for the hypothesis that an enhanced release of glutamate is a common mechanism in the action of hallucinogens.

DOM 2,5-Dimethoxy-4-Methylamphetamine↗

Effect of intravenous administration of D-lysergic acid diethylamide on initiation of protein synthesis in a cell-free system derived from brain.

An initiating cell-free protein synthesis system derived from brain was utilized to demonstrate that the intravenous injection of D-lysergic acid diethylamide (LSD) to rabbits resulted in a lesion at the initiation stage of brain protein synthesis. Three inhibitors of initiation, edeine, poly(I), and aurintricarboxylic acid were used to demonstrate a reduction in initiation-dependent amino acid incorporation in the brain cell-free system. One hour after LSD injection, there was also a measurable decrease in the formation of 40S and 80S initiation complexes in vitro, using either [35S]methionine or [35S]Met-tRNAf. Analysis of the methionine pool size after LSD administration indicated there was no change in methionine levels. Analysis of the formation of initiation complexes in the brain cell-free protein synthesis system prepared 6 h after LSD administration indicated that there was a return to control levels at this time. The effects of LSD on steps in the initiation process are thus reversible.

Animals↗

SEROTONIN BINDING TO NERVE-ENDING PARTICLES OF THE RAT BRAIN AND ITS INHIBITION BY LYSERGIC ACID DIETHYLAMIDE.

The binding of serotonin to nerve-ending particles and other preparations from rat brain has been examined. By investigating the amount bound as a function of serotonin concentration from 10(-7)M to 1O(-2)M, it was possible to identify three major components having K(assoc) (association constant) values of 2 x 10(6), 5 x 10(4), and 5 x 10(2). The component having the highest binding constant was not present in liver and appeared to be confined to the cortex and midbrain regions. This component is inhibited by d-lysergic acid diethylamide at low concentrations. Solubilization of this binding component has been achieved.

Brain↗

Effect of intravenous administration of d-lysergic acid diethylamide on subsequent protein synthesis in a cell-free system derived from brain.

An initiating cell-free protein synthesis system derived from brain was utilized to demonstrate that the intravenous injection of d-lysergic acid diethylamide (LSD) to rabbits induced a transient inhibition of translation following a brief stimulatory period. Subfractionation of the brain cell-free system into postribosomal supernatant (PRS) and microsome fractions demonstrated that LSD in vivo induced alterations in both of these fractions. In addition to the overall inhibition of translation in the cell-free system, differential effects were noted, i.e., greater than average relative decreases in in vitro labeling of certain brain proteins and relative increases in others. The brain proteins of molecular weights 75K and 95K, which were increased in relative labeling under conditions of LSD-induced hyperthermia, are similar in molecular weight to two of the major "heat shock" proteins reported in tissue culture systems. Injection of LSD to rabbits at 4 degrees C prevented LSD-induced hyperthermia but behavioral effects of the drug were still apparent. The overall decrease in cell-free translation was still observed but the differential labeling effects were not. LSD appeared to influence cell-free translation in the brain at two dissociable levels: (a) an overall decrease in translation that was observed even in the absence of LSD-induced hyperthermia and (b) differential labeling effects on particular proteins that were dependent on LSD-induced hyperthermia.

Animals↗

Immunoassay analysis of lysergic acid diethylamide.

Screening large numbers of urine samples for drugs of abuse is typically accomplished using immunoassays that allow for processing large numbers of samples without the requirement of sample preparation before analysis. Until fairly recently, screening of lysergic acid diethylamide (LSD) in urine samples could only be accomplished by the use of radioimmunoassays (RIA). Recently, new nonisotopic immunoassays have been developed for the screening of samples for LSD. These assays lend themselves to rapid, high-volume, automated analysis compared with RIA procedures. In order to evaluate the current commercially available assays, samples prepared at known concentrations were tested by each of the assays. In addition, samples from known use of LSD were tested and the performance of each of the assays compared. The assays examined in this study included RIA assays from Roche Diagnostics (Abuscreen) and Diagnostic Products (coat-a-count) and nonisotopic assays from Roche (OnLine), Behring (EMIT), Boehringer Mannheim (CEDIA), and STC (Microplate EIA). Assays that could readily be carried out in a semiquantitative mode (determining concentration based on a calibration curve) were evaluated as to their relative response to the samples tested. All of the assays evaluated identified all of the samples which confirmed positive by gas chromatography-mass spectrometry (GC-MS). Likewise, each of the assays identified some samples which did not confirm as positive by GC-MS.

Animals↗

Circannual variations in the binding of [3H]lysergic acid diethylamide to serotonin2A receptors and of [3H]paroxetine to serotonin uptake sites in platelets from healthy volunteers.

BACKGROUND: Circannual variations occur in several serotonergic parameters, including platelet serotonin uptake and platelet [3H]imipramine binding. METHODS: Binding of [3H]lysergic acid diethylamide ([3H]LSD) to platelet serotonin (5-HT)2A receptors and binding of [3H]paroxetine to platelet serotonin uptake sites were studied longitudinally for 1 year in 12 healthy volunteers. RESULTS: For [3H]LSD, the number of binding sites (Bmax) showed no significant seasonal variation (two-way analysis of variance), although Bmax was significantly higher during the months October through February than during the months April through August (32.6 vs. 29.8 fmol/mg protein; p = .015). For [3H]paroxetine, Bmax showed a significant seasonal variation (p = .003) with maximum in August (1322 fmol/mg protein) and minimum in February (1168 fmol/mg protein). The affinity constant (Kd) showed a significant seasonal variation for [3H]LSD binding (p = .046), but not for [3H]paroxetine binding. The seasonal fluctuations in [3H]LSD binding and in paroxetine binding tended to be inversely correlated for Bmax (r = -.70; p = .08) and were significantly negatively correlated for Kd (r = -.88; p = .009). CONCLUSIONS: The present study demonstrates a seasonal effect on platelet serotonin uptake site binding and indicates a possible seasonal effect on 5-HT2A receptor binding. The results imply that circannual fluctuations should be taken into account when these platelet serotonin markers are studied.

Adult↗

Release of [3H-noradrenaline from the motor adrenergic nerves of the anococcygeus muscle by lysergic acid diethylamide, tyramine or nerve stimulation.

1 A method is described for labelling the neuronal noradrenaline (NA) stores of rat anococcygeus with [3H]-NA and detecting subsequent release of 3H from the superfused tissue by nerve stimulation or drugs. 2 Lysergic acid diethylamide (LSD) or tyramine but not barium chloride or carbachol increased the efflux of 3H although each drug produced an equivalent contractile response. This confirms that LDS has an indirect sympathomimetic action. 3 LSD was found to produce a proportionately smaller reduction of the nerve-induced efflux of 3H than of the accompanying contractile response. 4 The inhibition of nerve-induced contractile responses by LSD was shown to be independent of the neuronal uptake of noradrenaline and any post-junctional inhibition demonstrated to be non-specific.

Animals↗